ADSL and infection: Other AMPs have also used zebrafish infection models to evaluate their in vivo effects, such as Scyreprocin, epinecidin-1, and fish-derived cathelicidins, with effect doses of 1–8 μg, 1–10 μg, and 10 μg per fish, respectively [15,65,66].